The Defiance Daily Target 2X Long HIMS ETF (HIMZ) is an actively managed, single-stock leveraged fund launched in March 2025. It aims to deliver two times (200%) the daily percentage change in the share price of Hims & Hers Health, primarily through swap agreements. This is fundamentally different from a traditional ETF that holds a diversified basket of stocks; HIMZ's entire performance is tied to one company, amplified by leverage.
That design explains the fund's extreme behavior. Its annualized standard deviation has been reported well above 100%, and its 52-week trading range spans from roughly $12 to several hundred dollars, reflecting both a 1-for-14 reverse split in March 2026 and the underlying stock's dramatic swings. The fund also carried a 1-for-14 reverse split in early 2026, and its net expense ratio sits near 1.29% to 1.31%, on top of the inherent leverage costs.
With HIMZ recently changing hands in the upper $20s to low $30s, a $50 price target represents a gain of roughly 50% to 85% from current levels. That is a meaningful move, yet not a fantastical one for a fund that has demonstrated this kind of volatility. Round-number levels like $50 tend to act as psychological magnets where traders concentrate orders, making them natural focal points for the question "can HIMZ reach $50?"
It is also a level with genuine distance from the present price. It is not a target that could be achieved in a single ordinary session, but it is close enough to remain plausible within a multi-week or multi-month horizon if the underlying catalyst environment improves.
Because HIMZ is a leveraged proxy for Hims & Hers, the bullish thesis rests squarely on the underlying company. Hims & Hers has built its growth narrative around GLP-1 weight-loss treatments, and analysts have highlighted strong demand signals from consumer credit-card data. The company has also diversified beyond GLP-1 medications into compounded peptides, hormone health, longevity, diagnostics, and AI-enabled healthcare tools.
Management has laid out ambitious long-term goals of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, and the company's acquisition of the digital-health platform Eucalyptus has extended its reach into the UK, Canada, Australia, and other markets. If Hims & Hers continues to beat quarterly expectations and raise guidance, the daily 2x leverage in HIMZ would mechanically translate those gains into outsized moves in the ETF itself.
The obstacles are significant. The most important is structural: leveraged ETFs are designed to match twice the daily return, not twice the long-term return. During choppy, range-bound markets, the daily reset of leverage causes what is known as volatility decay, which can erode a leveraged fund's value even when the underlying stock is roughly flat over time.
There are also fundamental risks tied to Hims & Hers itself. The company's reliance on compounded GLP-1 drugs exposes it to regulatory uncertainty from the U.S. Food and Drug Administration, and the telehealth weight-loss market is increasingly competitive. Any negative regulatory development, earnings disappointment, or broad rotation out of high-volatility healthcare names would hit HIMS first and be magnified in HIMZ. The fund's relatively small asset base and concentrated, non-diversified structure also amplify liquidity and tracking risks.
From a technical perspective, HIMZ's most relevant feature is its extraordinarily wide trading range rather than any single moving average or oscillator. A sustained move toward $50 would first require the fund to hold above its recent lows near the low $20s and then clear prior short-term resistance in the upper $30s to low $40s. Because the fund has traded far above $50 at times in its history, the $50 level itself is not an all-time barrier; it is a psychological and supply zone that the market has visited before.
On valuation, HIMZ does not have a traditional price-to-earnings ratio in the way a single company would. Its valuation is ultimately a leveraged expression of HIMS, whose own valuation has been a topic of sharp disagreement among Wall Street analysts. Some analysts have maintained price targets near $32 to $37 on HIMS with ratings ranging from hold to buy, underscoring that even the underlying stock's next move is far from consensus.
For traders monitoring highly volatile, single-stock leveraged instruments like HIMZ, timing matters enormously. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously scan thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. These signals can help traders identify opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening. Given the speed at which a 2x leveraged fund can move, having an automated, data-driven layer of market monitoring can be a useful complement to traditional research.
A move to $50 for HIMZ is plausible but far from assured. The single most important driver would be a sustained, multi-week advance in Hims & Hers Health, powered by continued GLP-1 demand, successful peptide and international expansion, and a favorable regulatory backdrop. In that scenario, the fund's 2x daily leverage could carry it to $50 relatively quickly.
Against that, the daily-reset structure works against long-term holders in choppy markets, and the underlying company faces genuine regulatory and competitive headwinds. Investors should monitor Hims & Hers quarterly results, FDA decisions on compounded GLP-1 and peptide products, and whether HIMZ can hold above its recent support zone. The $50 level is a realistic target, but it is a conditional one that depends on the underlying stock delivering durable gains rather than a single sharp bounce.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, HIMZ has been loosely correlated with TQQQ. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if HIMZ jumps, then TQQQ could also see price increases.
| Ticker / NAME | Correlation To HIMZ | 1D Price Change % | ||
|---|---|---|---|---|
| HIMZ | 100% | +0.29% | ||
| TQQQ - HIMZ | 41% Loosely correlated | +2.56% | ||
| QLD - HIMZ | -4% Poorly correlated | +1.74% | ||
| SOXL - HIMZ | -6% Poorly correlated | +5.23% | ||
| SPXL - HIMZ | -6% Poorly correlated | +2.43% | ||
| SSO - HIMZ | -6% Poorly correlated | +1.65% |